Journal article
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Abstract
Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, …
Authors
Holman RR; Bethel MA; Chan JCN; Chiasson J-L; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L
Journal
American Heart Journal, Vol. 168, No. 1, pp. 23–29.e2
Publisher
Elsevier
Publication Date
July 2014
DOI
10.1016/j.ahj.2014.03.021
ISSN
0002-8703